{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:15:28Z","timestamp":1791270928819,"version":"4.1.0"},"reference-count":65,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2007,4,1]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>The objective is to investigate whether polymorphisms with putative influence on fluorouracil\/oxaliplatin activity are associated with clinical outcomes of patients with advanced colorectal cancer treated with first-line oxaliplatin, folinic acid, and fluorouracil palliative chemotherapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and Methods<\/jats:title><jats:p>Consecutive patients were prospectively enrolled onto medical oncology units in Central Italy. Patients were required to have cytologically\/histologically confirmed metastatic disease with at least one measurable lesion. Peripheral blood samples were used for genotyping 12 polymorphisms in thymidylate synthase, methylenetetrahydrofolate reductase, xeroderma pigmentosum group D (XPD), excision repair cross complementing group 1 (ERCC1), x-ray cross complementing group 1, x-ray cross complementing protein 3, glutathione S-transferases (GSTs) genes. The primary end point of the study was to investigate the association between genotypes and progression-free survival (PFS).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In 166 patients, ERCC1-118 T\/T, XPD-751 A\/C, and XPD-751 C\/C genotypes were independently associated with adverse PFS. The presence of two risk genotypes (ERCC1-118 T\/T combined with either XPD-751 A\/C or XPD-751 C\/C) occurred in 50 patients (31%). This profiling showed an independent role for unfavorable PFS with a hazard ratio of 2.84% and 95% CI of 1.47 to 5.45 (P = .002). Neurotoxicity was significantly associated with GSTP1-105 A\/G. Carriers of the GSTP1-105 G\/G genotype were more prone to suffer from grade 3 neurotoxicity than carriers of GSTP1-105 A\/G and GSTP1-105 A\/A genotypes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>A pharmacogenetic approach may be an innovative strategy for optimizing palliative chemotherapy in patients with advanced colorectal cancer. These findings deserve confirmation in additional prospective studies.<\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.2006.08.1844","type":"journal-article","created":{"date-parts":[[2007,3,30]],"date-time":"2007-03-30T22:23:16Z","timestamp":1175293396000},"page":"1247-1254","source":"Crossref","is-referenced-by-count":220,"title":["Pharmacogenetic Profiling in Patients With Advanced Colorectal Cancer Treated With First-Line FOLFOX-4 Chemotherapy"],"prefix":"10.1200","volume":"25","author":[{"given":"Annamaria","family":"Ruzzo","sequence":"first","affiliation":[{"name":"From the Institute of Biochemistry G Fornaini, University of Urbino; Medical Oncology, Hospital of Urbino, Urbino; Medical Oncology, Hospital of Livorno, Livorno; Oncology Department, Istituto di Ricerche Farmacologiche Mario Negri, Milan; Medical Oncology, University Campus Biomedico, Rome; Medical Oncology, Hospital of Pesaro, Pesaro; Medical Oncology, Hospital of Senigallia, Senigallia; Medical Oncology, Hospital of Fermo, Fermo; Medical Oncology, University of Pisa, Pisa; Medical Oncology, Hospital..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Graziano","sequence":"additional","affiliation":[{"name":"From the Institute of Biochemistry G Fornaini, University of Urbino; Medical Oncology, Hospital of Urbino, Urbino; Medical Oncology, Hospital of Livorno, Livorno; Oncology Department, Istituto di Ricerche Farmacologiche Mario Negri, Milan; Medical Oncology, University Campus Biomedico, Rome; Medical Oncology, Hospital of Pesaro, Pesaro; Medical Oncology, Hospital of Senigallia, Senigallia; Medical Oncology, Hospital of Fermo, Fermo; Medical Oncology, University of Pisa, Pisa; Medical Oncology, Hospital..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fotios","family":"Loupakis","sequence":"additional","affiliation":[{"name":"From the Institute of Biochemistry G Fornaini, University of Urbino; Medical Oncology, Hospital of Urbino, Urbino; Medical Oncology, Hospital of Livorno, Livorno; Oncology Department, Istituto di Ricerche Farmacologiche Mario Negri, Milan; Medical Oncology, University Campus Biomedico, Rome; Medical Oncology, Hospital of Pesaro, Pesaro; Medical Oncology, Hospital of Senigallia, Senigallia; Medical Oncology, Hospital of Fermo, Fermo; Medical Oncology, University of Pisa, Pisa; Medical Oncology, Hospital..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliana","family":"Rulli","sequence":"additional","affiliation":[{"name":"From the Institute of Biochemistry G Fornaini, University of Urbino; Medical Oncology, Hospital of Urbino, Urbino; Medical Oncology, Hospital of Livorno, Livorno; Oncology Department, Istituto di Ricerche Farmacologiche Mario Negri, Milan; Medical Oncology, University Campus Biomedico, Rome; Medical Oncology, Hospital of Pesaro, Pesaro; Medical Oncology, Hospital of Senigallia, Senigallia; Medical Oncology, Hospital of Fermo, Fermo; Medical Oncology, University of Pisa, Pisa; Medical Oncology, Hospital..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Canestrari","sequence":"additional","affiliation":[{"name":"From the Institute of Biochemistry G Fornaini, University of Urbino; Medical Oncology, Hospital of Urbino, Urbino; Medical Oncology, Hospital of Livorno, Livorno; Oncology Department, Istituto di Ricerche Farmacologiche Mario Negri, Milan; Medical Oncology, University Campus Biomedico, Rome; Medical Oncology, Hospital of Pesaro, Pesaro; Medical Oncology, Hospital of Senigallia, Senigallia; Medical Oncology, Hospital of Fermo, Fermo; Medical Oncology, University of Pisa, Pisa; Medical Oncology, Hospital..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Santini","sequence":"additional","affiliation":[{"name":"From the Institute of Biochemistry G Fornaini, University of Urbino; Medical Oncology, Hospital of Urbino, Urbino; Medical Oncology, Hospital of Livorno, Livorno; Oncology Department, Istituto di Ricerche Farmacologiche Mario Negri, Milan; Medical Oncology, University Campus Biomedico, Rome; Medical Oncology, Hospital of Pesaro, Pesaro; Medical Oncology, Hospital of Senigallia, Senigallia; Medical Oncology, Hospital of Fermo, Fermo; Medical Oncology, University of Pisa, Pisa; Medical Oncology, Hospital..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Catalano","sequence":"additional","affiliation":[{"name":"From the Institute of Biochemistry G Fornaini, University of Urbino; Medical Oncology, Hospital of Urbino, Urbino; Medical Oncology, Hospital of Livorno, Livorno; Oncology Department, Istituto di Ricerche Farmacologiche Mario Negri, Milan; Medical Oncology, University Campus Biomedico, Rome; Medical Oncology, Hospital of Pesaro, Pesaro; Medical Oncology, Hospital of Senigallia, Senigallia; Medical Oncology, Hospital of Fermo, Fermo; Medical Oncology, University of Pisa, Pisa; Medical Oncology, Hospital..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Ficarelli","sequence":"additional","affiliation":[{"name":"From the Institute of Biochemistry G Fornaini, University of Urbino; Medical Oncology, Hospital of Urbino, Urbino; Medical Oncology, Hospital of Livorno, Livorno; Oncology Department, Istituto di Ricerche Farmacologiche Mario Negri, Milan; Medical Oncology, University Campus Biomedico, Rome; Medical Oncology, Hospital of Pesaro, Pesaro; Medical Oncology, Hospital of Senigallia, Senigallia; Medical Oncology, Hospital of Fermo, Fermo; Medical Oncology, University of Pisa, Pisa; Medical Oncology, Hospital..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Maltese","sequence":"additional","affiliation":[{"name":"From the Institute of Biochemistry G Fornaini, University of Urbino; Medical Oncology, Hospital of Urbino, Urbino; Medical Oncology, Hospital of Livorno, Livorno; Oncology Department, Istituto di Ricerche Farmacologiche Mario Negri, Milan; Medical Oncology, University Campus Biomedico, Rome; Medical Oncology, Hospital of Pesaro, Pesaro; Medical Oncology, Hospital of Senigallia, Senigallia; Medical Oncology, Hospital of Fermo, Fermo; Medical Oncology, University of Pisa, Pisa; Medical Oncology, Hospital..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Bisonni","sequence":"additional","affiliation":[{"name":"From the Institute of Biochemistry G Fornaini, University of Urbino; Medical Oncology, Hospital of Urbino, Urbino; Medical Oncology, Hospital of Livorno, Livorno; Oncology Department, Istituto di Ricerche Farmacologiche Mario Negri, Milan; Medical Oncology, University Campus Biomedico, Rome; Medical Oncology, Hospital of Pesaro, Pesaro; Medical Oncology, Hospital of Senigallia, Senigallia; Medical Oncology, Hospital of Fermo, Fermo; Medical Oncology, University of Pisa, Pisa; Medical Oncology, Hospital..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Masi","sequence":"additional","affiliation":[{"name":"From the Institute of Biochemistry G Fornaini, University of Urbino; Medical Oncology, Hospital of Urbino, Urbino; Medical Oncology, Hospital of Livorno, Livorno; Oncology Department, Istituto di Ricerche Farmacologiche Mario Negri, Milan; Medical Oncology, University Campus Biomedico, Rome; Medical Oncology, Hospital of Pesaro, Pesaro; Medical Oncology, Hospital of Senigallia, Senigallia; Medical Oncology, Hospital of Fermo, Fermo; Medical Oncology, University of Pisa, Pisa; Medical Oncology, Hospital..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaia","family":"Schiavon","sequence":"additional","affiliation":[{"name":"From the Institute of Biochemistry G Fornaini, University of Urbino; Medical Oncology, Hospital of Urbino, Urbino; Medical Oncology, Hospital of Livorno, Livorno; Oncology Department, Istituto di Ricerche Farmacologiche Mario Negri, Milan; Medical Oncology, University Campus Biomedico, Rome; Medical Oncology, Hospital of Pesaro, Pesaro; Medical Oncology, Hospital of Senigallia, Senigallia; Medical Oncology, Hospital of Fermo, Fermo; Medical Oncology, University of Pisa, Pisa; Medical Oncology, Hospital..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Giordani","sequence":"additional","affiliation":[{"name":"From the Institute of Biochemistry G Fornaini, University of Urbino; Medical Oncology, Hospital of Urbino, Urbino; Medical Oncology, Hospital of Livorno, Livorno; Oncology Department, Istituto di Ricerche Farmacologiche Mario Negri, Milan; Medical Oncology, University Campus Biomedico, Rome; Medical Oncology, Hospital of Pesaro, Pesaro; Medical Oncology, Hospital of Senigallia, Senigallia; Medical Oncology, Hospital of Fermo, Fermo; Medical Oncology, University of Pisa, Pisa; Medical Oncology, Hospital..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucio","family":"Giustini","sequence":"additional","affiliation":[{"name":"From the Institute of Biochemistry G Fornaini, University of Urbino; Medical Oncology, Hospital of Urbino, Urbino; Medical Oncology, Hospital of Livorno, Livorno; Oncology Department, Istituto di Ricerche Farmacologiche Mario Negri, Milan; Medical Oncology, University Campus Biomedico, Rome; Medical Oncology, Hospital of Pesaro, Pesaro; Medical Oncology, Hospital of Senigallia, Senigallia; Medical Oncology, Hospital of Fermo, Fermo; Medical Oncology, University of Pisa, Pisa; Medical Oncology, Hospital..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Falcone","sequence":"additional","affiliation":[{"name":"From the Institute of Biochemistry G Fornaini, University of Urbino; Medical Oncology, Hospital of Urbino, Urbino; Medical Oncology, Hospital of Livorno, Livorno; Oncology Department, Istituto di Ricerche Farmacologiche Mario Negri, Milan; Medical Oncology, University Campus Biomedico, Rome; Medical Oncology, Hospital of Pesaro, Pesaro; Medical Oncology, Hospital of Senigallia, Senigallia; Medical Oncology, Hospital of Fermo, Fermo; Medical Oncology, University of Pisa, Pisa; Medical Oncology, Hospital..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Tonini","sequence":"additional","affiliation":[{"name":"From the Institute of Biochemistry G Fornaini, University of Urbino; Medical Oncology, Hospital of Urbino, Urbino; Medical Oncology, Hospital of Livorno, Livorno; Oncology Department, Istituto di Ricerche Farmacologiche Mario Negri, Milan; Medical Oncology, University Campus Biomedico, Rome; Medical Oncology, Hospital of Pesaro, Pesaro; Medical Oncology, Hospital of Senigallia, Senigallia; Medical Oncology, Hospital of Fermo, Fermo; Medical Oncology, University of Pisa, Pisa; Medical Oncology, Hospital..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosarita","family":"Silva","sequence":"additional","affiliation":[{"name":"From the Institute of Biochemistry G Fornaini, University of Urbino; Medical Oncology, Hospital of Urbino, Urbino; Medical Oncology, Hospital of Livorno, Livorno; Oncology Department, Istituto di Ricerche Farmacologiche Mario Negri, Milan; Medical Oncology, University Campus Biomedico, Rome; Medical Oncology, Hospital of Pesaro, Pesaro; Medical Oncology, Hospital of Senigallia, Senigallia; Medical Oncology, Hospital of Fermo, Fermo; Medical Oncology, University of Pisa, Pisa; Medical Oncology, Hospital..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodolfo","family":"Mattioli","sequence":"additional","affiliation":[{"name":"From the Institute of Biochemistry G Fornaini, University of Urbino; Medical Oncology, Hospital of Urbino, Urbino; Medical Oncology, Hospital of Livorno, Livorno; Oncology Department, Istituto di Ricerche Farmacologiche Mario Negri, Milan; Medical Oncology, University Campus Biomedico, Rome; Medical Oncology, Hospital of Pesaro, Pesaro; Medical Oncology, Hospital of Senigallia, Senigallia; Medical Oncology, Hospital of Fermo, Fermo; Medical Oncology, University of Pisa, Pisa; Medical Oncology, Hospital..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Floriani","sequence":"additional","affiliation":[{"name":"From the Institute of Biochemistry G Fornaini, University of Urbino; Medical Oncology, Hospital of Urbino, Urbino; Medical Oncology, Hospital of Livorno, Livorno; Oncology Department, Istituto di Ricerche Farmacologiche Mario Negri, Milan; Medical Oncology, University Campus Biomedico, Rome; Medical Oncology, Hospital of Pesaro, Pesaro; Medical Oncology, Hospital of Senigallia, Senigallia; Medical Oncology, Hospital of Fermo, Fermo; Medical Oncology, University of Pisa, Pisa; Medical Oncology, Hospital..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Magnani","sequence":"additional","affiliation":[{"name":"From the Institute of Biochemistry G Fornaini, University of Urbino; Medical Oncology, Hospital of Urbino, Urbino; Medical Oncology, Hospital of Livorno, Livorno; Oncology Department, Istituto di Ricerche Farmacologiche Mario Negri, Milan; Medical Oncology, University Campus Biomedico, Rome; Medical Oncology, Hospital of Pesaro, Pesaro; Medical Oncology, Hospital of Senigallia, Senigallia; Medical Oncology, Hospital of Fermo, Fermo; Medical Oncology, University of Pisa, Pisa; Medical Oncology, Hospital..."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.16.2938"},{"key":"R2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.17.749"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.12.075"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601487"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.med.54.101601.152352"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2004.22.14_suppl.529"},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.1247\/csf.20.191"},{"key":"R8","unstructured":"Kawakami K, Watanabe G: Identification and functional analysis of single nucleotide polymorphism in the tandem repeat sequence of the thymidylate synthase gene. Cancer Res 63:6004,2003-6007,"},{"key":"R9","unstructured":"Mandola MV, Stoehlmacher J, Muller-Weeks S, et al: A novel single nucleotide polymorphism within the 5\u2032 tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity. Cancer Res 63:2898,2003-2904,"},{"key":"R10","unstructured":"Kawakami K, Omura K, Kanehira E, et al: Polymorphic tandem repeats in the thymidylate synthase gene is associated with its protein expression in human gastrointestinal cancers. Anticancer Res 19:3249,1999-3252,"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2005.06.016"},{"key":"R12","unstructured":"Kawakami K, Watanabe G: The association of thymidylate synthase mRNA expression with its three gene polymorphisms in colorectal cancer. Proc Am Assoc Cancer Res 45:484,2004, (abstr 2104)"},{"key":"R13","unstructured":"Ulrich CM, Bigler J, Velicer CM, et al: Searching expressed sequence Tag databases: Discovery and confirmation of a common polymorphism in the thymidylate synthase gene. Cancer Epidemiol Biomarkers Prev 9:1381,2000-1385,"},{"key":"R14","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-200405000-00007"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djh015"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601523"},{"key":"R17","unstructured":"Kawakami K, Ruszkiewicz A, Bennett G, et al: The folate pool in colorectal cancers is associated with DNA hypermethylation and with a polymorphism in methylenetetrahydrofolate reductase. Clin Cancer Res 9:5860,2003-5865,"},{"key":"R18","unstructured":"Paz MF, Avila S, Fraga MF, et al: Germ-line variants in methyl-group metabolism genes and susceptibility to DNA methylation in normal tissues and human primary tumors. Cancer Res 62:4519,2002-4524,"},{"key":"R19","doi-asserted-by":"publisher","DOI":"10.1615\/CritRevOncog.v12.i1-2.10"},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.1038\/nrd1691"},{"key":"R21","doi-asserted-by":"crossref","unstructured":"Altaha R, Liang X, Yu JJ, et al: Excision repair cross complementing-group 1: Gene expression and platinum resistance. Int J Mol Med 14:959,2004-970,","DOI":"10.3892\/ijmm.14.6.959"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-4-18"},{"key":"R23","unstructured":"Furuta T, Ueda T, Aune G, et al: Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res 62:4899,2002-4902,"},{"key":"R24","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.105.084053"},{"key":"R25","unstructured":"Raaphorst GP, Li LF, Yang DP: Evaluation of adaptive responses to cisplatin in normal and mutant cell lines with mutations in recombination repair pathways. Anticancer Res 26:1183,2006-1187,"},{"key":"R26","unstructured":"Park DJ, Stoehlmacher J, Zhang W, et al: ERCC1 polymorphism is associated with differential ERCC1 mRNA levels. Proc Am Ass Cancer Res 43:321,2002, (abstr. 1591)"},{"key":"R27","doi-asserted-by":"crossref","unstructured":"Savas S, Kim DY, Ahmad MF, et al: Identifying functional genetic variants in DNA repair pathway using protein conservation analysis. Cancer Epidemiol Biomarkers Prev 13:801,2004-807,","DOI":"10.1158\/1055-9965.801.13.5"},{"key":"R28","unstructured":"Lunn RM, Langlois RG, Hsieh LL, et al: XRCC1 polymorphisms: Effects on aflatoxin B1-DNA adducts and glycophorin A variant frequency. Cancer Res 59:2557,1999-2561,"},{"key":"R29","doi-asserted-by":"publisher","DOI":"10.1289\/ehp.6632"},{"key":"R30","doi-asserted-by":"publisher","DOI":"10.1002\/em.20032"},{"key":"R31","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/21.4.551"},{"key":"R32","unstructured":"Spitz MR, Wu X, Wang Y, et al: Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res 61:1354,2001-1357,"},{"key":"R33","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1205539"},{"key":"R34","unstructured":"Seker H, Butkiewicz D, Bowman ED, et al: Functional significance of XPD polymorphic variants: Attenuated apoptosis in human lymphoblastoid cells with the XPD 312 Asp\/Asp genotype. Cancer Res 61:7430,2001-7434,"},{"key":"R35","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/19.2.275"},{"key":"R36","doi-asserted-by":"publisher","DOI":"10.1080\/10715769900301121"},{"key":"R37","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3835(96)04832-X"},{"key":"R38","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20010601)91:11<2033::AID-CNCR1229>3.0.CO;2-J"},{"key":"R39","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.3.205"},{"key":"R40","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-2076"},{"key":"R41","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(90)90005-M"},{"key":"R42","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-200204000-00008"},{"key":"R43","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(00)00286-0"},{"key":"R44","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi244"},{"key":"R45","doi-asserted-by":"publisher","DOI":"10.1038\/sj.tpj.6500012"},{"key":"R46","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601975"},{"key":"R47","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.06.219"},{"key":"R48","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.5253"},{"key":"R49","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.20487"},{"key":"R50","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M600282200"},{"key":"R51","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-0200-03"},{"key":"R52","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-004-0985-9"},{"key":"R53","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.1.368"},{"key":"R54","unstructured":"Cohen V, Panet-Raymond V, Sabbaghian N, et al: Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: A novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy. Clin Cancer Res 9:1611,2003-1615,"},{"key":"R55","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-200412000-00001"},{"key":"R56","unstructured":"Marcuello E, Altes A, Menoyo A, et al: Methylenetetrahydrofolate reductase gene polymorphisms: Genomic predictors of clinical response to fluoropyrimidine-based chemotherapy? Cancer Chemother Pharmacol 5:1,2005-6,"},{"key":"R57","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2004.12.006"},{"key":"R58","unstructured":"Park DJ, Zhang W, Stoehlmacher J, et al: ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy. Clin Adv Hematol Oncol 1:162,2003-166,"},{"key":"R59","unstructured":"Park DJ, Stoehlmacher J, Zhang W, et al: A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res 61:8654,2001-8658,"},{"key":"R60","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/94.12.936"},{"key":"R61","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/11.3.451"},{"key":"R62","unstructured":"Moscow JA, Fairchild CR, Madden MJ, et al: Expression of anionic glutathione-S-transferase and P-glycoprotein genes in human tissues and tumors. Cancer Res 49:1422,1989-1428,"},{"key":"R63","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-0774.2003.tb00158.x"},{"key":"R64","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1206940"},{"key":"R65","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.06.023"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2006.08.1844","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T07:13:28Z","timestamp":1683789208000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2006.08.1844"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4,1]]},"references-count":65,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2007,4,1]]}},"alternative-id":["10.1200\/JCO.2006.08.1844"],"URL":"https:\/\/doi.org\/10.1200\/jco.2006.08.1844","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,4,1]]}}}